Related Experiment Videos
Local and systemic thrombolytic therapy for acute deep venous thrombosis
M C H Janssen1, H Wollersheim, L J Schultze-Kool
1Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. M.Janssen@aig.umcn.nl
The Netherlands Journal of Medicine
|April 9, 2005
Summary
Systemic and catheter-directed thrombolysis for deep venous thrombosis (DVT) offer faster clot resolution but carry higher risks. Current evidence suggests conventional anticoagulation remains the preferred treatment for most DVT patients.
Area of Science:
- Vascular Medicine
- Interventional Cardiology
- Thrombosis Management
Background:
- Standard anticoagulation for deep venous thrombosis (DVT) may not prevent post-thrombotic syndrome (PTS).
- Thrombolytic agents offer potential for more complete clot lysis, possibly reducing long-term venous complications.
Purpose of the Study:
- To review the efficacy and safety of systemic thrombolysis, catheter-directed thrombolysis (CDT), and percutaneous mechanical thrombectomy (PMT) for lower-extremity DVT.
- To compare these interventions with conventional anticoagulation therapy regarding PTS development and complication rates.
Main Methods:
- Review of existing literature on thrombolytic and mechanical thrombectomy treatments for DVT.
- Analysis of data on clot resolution, post-thrombotic syndrome incidence, and complication rates associated with different DVT treatment modalities.
Main Results:
- Thrombolytic therapy demonstrates greater clot lysis but is associated with higher complication rates, including 11% major bleeding.
- While PTS incidence may be lower with thrombolytics, methodological limitations in studies hinder definitive conclusions.
- No adequate randomized controlled trials directly compare CDT or PMT with conventional therapy.
Conclusions:
- Thrombolytic therapy, CDT, and PMT are not recommended for routine DVT treatment due to uncertain long-term benefits in preventing PTS and higher risks.
- Conventional anticoagulation therapy remains a relatively safe, cost-effective, and convenient option for most patients with DVT.